AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38797872 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 536
Study 38797892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab (50-1,000 mg i.v. every 4 weeks for induction; 200 mg s.c. every 4 or 12 weeks for maintenance)
Number of subjects: 0
Study 38797892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0
Study 38798356 — intervention group
Group type: EXPERIMENTAL
Intervention: mFCCA short version
Number of subjects: 318
Study 38798396 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel non-invasive biomarkers of GERD, BE, airway hyperreactivity (AHR), treatment efficacy, and severity of symptoms.
Number of subjects: 0
Study 38798396 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of Reflux disease.
Number of subjects: 0
Study 38798481 — intervention group
Group type: EXPERIMENTAL
Intervention: TARANG intervention (4-month intervention with light touch engagement of husbands, 4 sessions)
Number of subjects: 41
Study 38798524 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 14 days
Number of subjects: 1250
Study 38798524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study 38798524 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1250
Study 38798539 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h time restricted eating (TRE)
Number of subjects: 90
Study 38798539 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily calorie restriction (CR)
Number of subjects: 90
Study 38798539 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 38798539 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal females (Estradiol, Estrone, Progesterone)
Number of subjects: 90
Study 38798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated sleep staging algorithm (SeqSleepNet) using three channels: C4-A1, EOG, and chin EMG.
Number of subjects: 176
Study 38798709 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated sleep staging algorithm (SeqSleepNet) in children with DRE.
Number of subjects: 176
Study 38798893 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert-Ultra assay with stool samples
Number of subjects: 563
Study 38798893 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert-Ultra assay with urine samples
Number of subjects: 563
Study 38798893 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (RS)
Number of subjects: 563
Study 38798902 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement behavior compositions (12.1 h of sleep, 4.7 h of sedentary time, 5.6 h of light physical activity, 1.7 h of MVPA)
Number of subjects: 388
Study 38798902 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement behavior compositions
Number of subjects: 388
Study 38799274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (up to once daily as needed for 52 weeks)
Number of subjects: 1800
Study 38799276 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS bottles containing opioid medication for a 90-day period
Number of subjects: 28
Study 38799276 — intervention group
Group type: COMPARATOR
Intervention: Standard medication bottles
Number of subjects: 28
Study 38799276 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS data
Number of subjects: 28
Study 38799438 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM granules (9g/sachet, two times daily) for 7 days
Number of subjects: 2163
Study 38799438 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 2163
Study 38799438 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM granules
Number of subjects: 2163
Study 38800061 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy for insomnia (iCBT-I) for 2 months
Number of subjects: 0
Study 38800061 — intervention group
Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 0
Study 38800061 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Number of subjects: 0
Study 38800121 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide hemostatic (PH) topical product
Number of subjects: 324
Study 38800121 — intervention group
Group type: COMPARATOR
Intervention: Microporous polysaccharide hemospheres (MPH)
Number of subjects: 324
Study 38800350 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute handgrip and isometric exercises (pulling and pushing)
Number of subjects: 30
Study 38800350 — intervention group
Group type: COMPARATOR
Intervention: 10-minute healthy-diet videos
Number of subjects: 30
Study 38800408 — intervention group
Group type: EXPERIMENTAL
Intervention: DPCP 0.04% ointment applied twice weekly to four in-transit metastases, concurrent with pembrolizumab 300 mg every three weeks.
Number of subjects: 1
Study 38800408 — intervention group
Group type: EXPERIMENTAL
Intervention: DPCP 0.04% ointment
Number of subjects: 1
Study 38800632 — intervention group
Group type: EXPERIMENTAL
Intervention: O-BD
Number of subjects: 393
Study 38800632 — intervention group
Group type: EXPERIMENTAL
Intervention: O-BD (aged under 12 years)
Number of subjects: 393
Study 38800632 — intervention group
Group type: EXPERIMENTAL
Intervention: O-BD (aged 12 years and over)
Number of subjects: 393
Study 38800678 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-2
Number of subjects: 0
Study 38800678 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-2
Number of subjects: 0
Study 38800678 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-2 and PHQ-2
Number of subjects: 0
Study 38800802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 689
Study 38800822 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone
Number of subjects: 78
Study 38800822 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone
Number of subjects: 78
Study 38800822 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg triamcinolone
Number of subjects: 78
Study 38800822 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study 38801306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) with high-frequency oscillatory ventilation (HFOV)
Number of subjects: 600
Study 38801306 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning with conventional mechanical ventilation (CMV)
Number of subjects: 600
Study 38801306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) with conventional mechanical ventilation (CMV)
Number of subjects: 600
Study 38801306 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine positioning with high-frequency oscillatory ventilation (HFOV)
Number of subjects: 600
Study 38801306 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 600
Study 38801597 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactinoma patients
Number of subjects: 38
Study 38801597 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 38801606 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 16 weeks plus existing topical therapy
Number of subjects: 134
Study 38801641 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Chinese medicine (CM) treatment ≥3 months
Number of subjects: 2001
Study 38801641 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (non-CM cohort)
Number of subjects: 2001
Study 38801774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined extracorporeal shock-wave lithotripsy (ESWL) and endoscopic retrograde pancreatography (ERP)
Number of subjects: 106
Study 38801774 — intervention group
Group type: COMPARATOR
Intervention: Sham procedures
Number of subjects: 106
Study 38801826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-RSV preF protein (one intramuscular injection)
Number of subjects: 5782
Study 38801826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5782
Study 38801945 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) at 25-40 Gy/5 fractions per tumor volume
Number of subjects: 85
Study 38801945 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) at 37.5 Gy/15 fractions
Number of subjects: 85
Study 38801945 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT)
Number of subjects: 85
Study 38802053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 466
Study 38802053 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 466
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health technologies, real-time self-reports, and qualitative interview data
Number of subjects: 40
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of mental and physical fatigue via smartphone app
Number of subjects: 40
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated fatigue and affect questionnaires
Number of subjects: 40
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-study interviews
Number of subjects: 40
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback session offered to participants
Number of subjects: 40
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG patches and wearable bracelet
Number of subjects: 40
Study 38802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable bracelet and environment beacons
Number of subjects: 40
Study 38802281 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-CBT
Number of subjects: 90
Study 38802281 — intervention group
Group type: COMPARATOR
Intervention: TAU+ME
Number of subjects: 90
Study 38802370 — intervention group
Group type: EXPERIMENTAL
Intervention: High environmental pollution exposure
Number of subjects: 359
Study 38802370 — intervention group
Group type: COMPARATOR
Intervention: Medium environmental pollution exposure
Number of subjects: 359
Study 38802370 — intervention group
Group type: COMPARATOR
Intervention: Low environmental pollution exposure
Number of subjects: 359
Study 38802399 — intervention group
Group type: EXPERIMENTAL
Intervention: QCS-based patient stratification
Number of subjects: 151
Study 38802399 — intervention group
Group type: COMPARATOR
Intervention: Manual scoring based on ASCO/CAP guidelines
Number of subjects: 151
Study 38802569 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amniotic epithelial stem cells (hAESCs) injected on day -1 or day 7 post-PBMC infusion
Number of subjects: 100
Study 38802569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 38802634 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat in combination with imiglucerase
Number of subjects: 11
Study 38802635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 0
Study 38802635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 0
Study 38802635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38802811 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO-PEN interventions
Number of subjects: 0
Study 38802811 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 0
Study 38802866 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM therapy (n=48)
Number of subjects: 95
Study 38802866 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) (n=47)
Number of subjects: 95
Study 38802866 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM therapy
Number of subjects: 95
Study 38802866 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 95
Study 38802888 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT with SIB (40 Gy in 15 fractions, SIB of 48 Gy in 15 fractions to the tumor bed)
Number of subjects: 2904
Study 38802888 — intervention group
Group type: COMPARATOR
Intervention: CFRT with sequential boost (50 Gy in 25 fractions, sequential boost of 10 Gy in 5 fractions to the tumor bed)
Number of subjects: 2904
Study 38803220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based chemotherapy plus therapeutic plasmapheresis (TPP) with 4% human albumin solution
Number of subjects: 119
Study 38803252 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community of practice (VCoP) - online social interaction for 12 months
Number of subjects: 0
Study 38803252 — intervention group
Group type: COMPARATOR
Intervention: Individualised online self-management education (control) - delivered individually for 12 months
Number of subjects: 0
Study 38803252 — intervention group
Group type: EXPERIMENTAL
Intervention: VCoP
Number of subjects: 0
Study 38803252 — intervention group
Group type: COMPARATOR
Intervention: Individualised online self-management education (control)
Number of subjects: 0
Study 38803266 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise (n=54)
Number of subjects: 161
Study 38803266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=53)
Number of subjects: 161
Study 38803266 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=54)
Number of subjects: 161
Study 38803412 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5475
Number of subjects: 23
Study 38803412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 38803549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 0
Study 38803549 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 38803611 — intervention group
Group type: EXPERIMENTAL
Intervention: Time for Living and Caring (TLC) intervention
Number of subjects: 0
Study 38803628 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg with a targeted prescribing pathway
Number of subjects: 392
Study 38803628 — intervention group
Group type: COMPARATOR
Intervention: Standard SWMS care
Number of subjects: 392
Study 38803637 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 50
Study 38803637 — intervention group
Group type: COMPARATOR
Intervention: Tablet
Number of subjects: 50
Study 38803693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Ketogenic Nutrition Adherence (MKNA) Program
Number of subjects: 58
Study 38803693 — intervention group
Group type: COMPARATOR
Intervention: MKN Education (MKNE) program
Number of subjects: 58
Study 38803811 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Art Plus intervention
Number of subjects: 0
Study 38803811 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 38803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine exosomal peptides after thyroidectomy
Number of subjects: 70
Study 38803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum proteins and urine exosomal peptides
Number of subjects: 70
Study 38803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Known risk factors for high-risk thyroid cancer
Number of subjects: 70
Study 38803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrations of serum proteins or urine exosomal peptides
Number of subjects: 70
Study 38804134 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 168
Study 38804134 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 168
Study 38804148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day
Number of subjects: 220
Study 38804148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 38804183 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised lifestyle programme
Number of subjects: 0
Study 38804183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38804212 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3366
Number of subjects: 104
Study 38804212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 38804514 — intervention group
Group type: EXPERIMENTAL
Intervention: Felzartamab (16 mg/kg)
Number of subjects: 22
Study 38804514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 38804514 — intervention group
Group type: EXPERIMENTAL
Intervention: Felzartamab
Number of subjects: 22
Study 38804517 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran 10 mg (quarterly dose)
Number of subjects: 353
Study 38804517 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran 25 mg (quarterly dose)
Number of subjects: 353
Study 38804517 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran 50 mg (quarterly dose)
Number of subjects: 353
Study 38804517 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran 50 mg (half-yearly dose)
Number of subjects: 353
Study 38804517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 38804779 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut consumption group (ad libitum peanut consumption from infancy to age 5 years)
Number of subjects: 508
Study 38804779 — intervention group
Group type: COMPARATOR
Intervention: Peanut avoidance group (avoided peanuts from infancy to age 5 years)
Number of subjects: 508
Study 38804782 — intervention group
Group type: EXPERIMENTAL
Intervention: CK0801 Treg cell therapy
Number of subjects: 9
Study 38804790 — intervention group
Group type: EXPERIMENTAL
Intervention: Olgotrelvir 600 mg twice daily for 5 days
Number of subjects: 1212
Study 38804790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study 38804903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS) 2.2, non-mentholated
Number of subjects: 984
Study 38804903 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 984
Study 38805037 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide maintenance
Number of subjects: 85
Study 38805037 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 85
Study 38805037 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 85
Study 38805069 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAs 904 nm PBM at 10 J/cm²
Number of subjects: 0
Study 38805069 — intervention group
Group type: COMPARATOR
Intervention: GaAs 904 nm PBM (all dosages)
Number of subjects: 0
Study 38805199 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily meditation
Number of subjects: 247
Study 38805199 — intervention group
Group type: COMPARATOR
Intervention: Once-daily meditation
Number of subjects: 247
Study 38805199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app introduction
Number of subjects: 247
Study 38805199 — intervention group
Group type: COMPARATOR
Intervention: Therapist call introduction
Number of subjects: 247
Study 38805199 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based management of increasing symptoms
Number of subjects: 247
Study 38805199 — intervention group
Group type: COMPARATOR
Intervention: Therapist call management of increasing symptoms
Number of subjects: 247
Study 38805207 — intervention group
Group type: EXPERIMENTAL
Intervention: Early DOAC initiation (within 48 hours for minor/moderate stroke; days 6-7 for major stroke)
Number of subjects: 1962
Study 38805207 — intervention group
Group type: COMPARATOR
Intervention: Late DOAC initiation (days 3-4 for minor stroke; days 6-7 for moderate stroke; days 12-14 for major stroke)
Number of subjects: 1962
Study 38805207 — intervention group
Group type: EXPERIMENTAL
Intervention: Early DOAC initiation
Number of subjects: 1962
Study 38805207 — intervention group
Group type: COMPARATOR
Intervention: Late DOAC initiation
Number of subjects: 1962
Study 38805213 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG3667, a selective ATP competitive TYK2 inhibitor, dosage and duration not available
Number of subjects: 0
Study 38805216 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-intensive atorvastatin (80 mg daily on days 1-21; 40 mg daily on days 22-90)
Number of subjects: 6100
Study 38805216 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intensive statin (placebo for days 1-3, followed by atorvastatin 40 mg daily on days 4-21, and then atorvastatin 40 mg daily on days 22-90)
Number of subjects: 6100
Study 38805216 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-intensive atorvastatin
Number of subjects: 6100
Study 38805216 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intensive statin
Number of subjects: 6100
Study 38805228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal natural progesterone therapy
Number of subjects: 102
Study 38805228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 38805242 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1703 (20 mg)
Number of subjects: 42
Study 38805242 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1703 (75 mg)
Number of subjects: 42
Study 38805242 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1703 (150 mg)
Number of subjects: 42
Study 38805242 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1703 (300 mg)
Number of subjects: 42
Study 38805242 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1703 (400 mg)
Number of subjects: 42
Study 38805242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 38805251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled BP monitoring and digital cognitive assessments for 6 months
Number of subjects: 71
Study 38805251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled BP monitoring
Number of subjects: 71
Study 38805251 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive assessments
Number of subjects: 71
Study 38805251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth self-measured BP (SMBP) monitoring
Number of subjects: 71
Study 38805253 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based lifestyle coaching program delivered via SMS and mobile app
Number of subjects: 141
Study 38805253 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based lifestyle coaching program
Number of subjects: 141
Study 38805264 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Preferences for Patient Participation (4Ps) tool
Number of subjects: 949